8-K

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 28, 2012

TRANZYME, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	001-35119	63-1192270
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of		Identification No.)
incorporation)

5001 South Miami Boulevard, Suite 300
Durham, NC	27703
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (919) 474-0020

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On November 28, 2012, Tranzyme, Inc. (the “Company”) participated in the 24th Annual Piper Jaffray Healthcare Conference in New York, New York, and held one-on-one discussions with investors using defined presentation materials.  A copy of the Company’s presentation materials has been posted to the Company’s website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibits, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This Current Report on Form 8-K and the presentations include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the progress and timing of clinical trials, the safety and efficacy of the Company’s product candidates, its collaborators, and estimates of the potential markets for the Company’s product candidates. Typically, these statements contain words such as “believe”,  “anticipate”, “plan”, “intend”, and similar expressions. These and other forward-looking statements speak only as of the date of the 8-K and the presentations and are subject to substantial risks and uncertainties and other important factors that may cause the Company’s actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by forward-looking statements. Additional risks and uncertainties are described more fully in the Company’s Form 10-Q for the quarter ended September 30, 2012 filed on November 9, 2012 and other periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to update any of the forward-looking statements except as required by law.

Item 9.01.             Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.	Description
99.1	Presentation dated November 28, 2012

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

November 28, 2012	Tranzyme, Inc.
	By:	/s/ Vipin K. Garg, Ph.D.
	Name:	Vipin K. Garg, Ph.D.
	Title:	President and Chief Executive Officer

3

EX-99.1

Exhibit 99.1

November 28, 2012

Safe Harbor Statement Certain items in this presentation and other matters discussed today or answers that may be given to questions asked could constitute forward-looking statements, including statements regarding the progress and timing of clinical trials, the safety and efficacy of our product candidates, our collaborators, and estimates of the potential markets for our product candidates. Typically, these statements contain words such as “believe”, “anticipate”, “plan”, “intend”, and similar expressions. These and other forward-looking statements speak only as of the date of this Presentation and are subject to substantial risks and uncertainties and other important factors that may cause Tranzyme’s actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by forward-looking statements. Additional risks and uncertainties are described more fully in Tranzyme’s Form 10-Q for the quarter ended September 30, 2012 filed on November 9, 2012. Please note that Tranzyme undertakes no obligation to update any of the forward-looking statements discussed today.

TZP-102-G003 Phase 2b Top-Line Results

TZP-102 Phase 2b Trial Design 12-week, double-blind, US & EU, placebo-controlled trial Once daily oral administration of 10mg, 20mg TZP-102 or placebo 201 patients; 43 sites Efficacy assessment: Primary Endpoint: Change from baseline in the average GSDD composite score at end of treatment Gastroparesis Symptoms Daily Diary (GSDD) Nausea Early Satiety Bloating Upper Abdominal Pain Secondary Endpoints: Change from baseline in individual symptoms Change from baseline in the average GCSI (Gastroparesis Cardinal Symptom Index; 9 symptom composite score) at end of treatment

TZP-102 Phase 2b Results: GSDD Week 4

TZP-102 Phase 2b Results: GSDD Week 12

TZP-102 Phase 2b Results: Mean Change in Symptoms at Week 4 Mean Change in Daily Diary Individual Symptom Score from Baseline to End of Week 4 Symptom Placebo (n=64) 10mg (n=66) 20mg (n=65) All TZP-102 Doses (n=131) Nausea -0.96 -1.25 -0.93 -1.09 Early Satiety -0.84 -1.20 -0.96 -1.08 Bloating -0.96 -0.97 -0.93 -0.95 Upper Abdominal Pain -0.92 -1.12 -1.11 -1.11 GSDD Composite Score -0.92 -1.13 -0.98 -1.06 Principal symptoms of gastroparesis

TZP-102 Phase 2b Results: Mean Change in Symptoms at Week 12 Mean Change in Daily Diary Individual Symptom Score from Baseline to End of Week 12 Symptom Placebo (n=64) 10mg (n=66) 20mg (n=65) All TZP-102 Doses (n=131) Nausea -1.53 -1.84 -1.37 -1.61 Early Satiety -1.41 -1.76 -1.47 -1.62 Bloating -1.57 -1.51 -1.37 -1.44 Upper Abdominal Pain -1.33 -1.71 -1.52 -1.61 GSDD Composite Score -1.46 -1.70 -1.43 -1.57 Principal symptoms of gastroparesis

TZP-102 Phase 2b Results: GCSI Week 4

TZP-102 Phase 2b Results: GCSI Week 12

TZP-102 Phase 2b Safety Both doses well tolerated No significant differences between the doses or dose-dependent trends No significant metabolic changes throughout 12-week treatment period Body weight Glucose HbA1c

TZP-102 DIGEST Trial (2nd Phase 2b) Primary Endpoint: Change from baseline in the average GSDD composite score at end of treatment 12-week, double-blind, US & EU, placebo-controlled trial Three times daily oral administration of 10mg TZP-102 or placebo before meals ~120 patients; ~35 sites Enrollment ongoing Efficacy assessment: Gastroparesis Symptoms Daily Diary (GSDD) plus Vomiting and Retching Nausea Early Satiety Bloating Upper Abdominal Pain Planned enrollment completion: Q1 2013 Top-line results: H1 2013

TZP-102 Next Steps Interim data review (including futility analysis) planned for DIGEST before year-end Approximately 60 patients (30 per arm) data through treatment week 4 Enrollment completion: Q1 2013 Top-line data expected: H1 2013 EOP2 meeting with the FDA: H2 2013